Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages

  Inaba, Hiroto ^a   Londero, Margherita ^a,b   Maurer, Scott H ^a   Onciu, Mihaela ^a   Ge, Yubin ^c   Taub, Jeffrey W ^c   Rubnitz, Jeffrey E ^a   Raimondi, Susana C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DOWN SYNDROME; FEMALE; GENE MUTATION; HEMATOCHEZIA; HUMAN; INFANT; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; DOWN SYNDROME; FEMALE; GATA1 TRANSCRIPTION FACTOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 79952745049     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.3634     Document Type: Article

References (10)

1. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
2. Xavier AC, Ge Y, Taub JW: Down syndrome and malignancies: A unique clinical relationship - A paper from the 2008 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn 11:371-380, 2009
3. Gamis AS, Hilden JM: Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: Does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol 24:2-5, 2002
4. Apollonsky N, Shende A, Ouansafi I, et al: Transient myeloproliferative disorder in neonates with and without Down syndrome: A tale of 2 syndromes. J Pediatr Hematol Oncol 30:860-864, 2008
5. Wechsler J, Greene M, McDevitt MA, et al: Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32:148-152, 2002 (Pubitemid 34977210)
6. Hollanda LM, Lima CS, Cunha AF, et al: An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38:807-812, 2006 (Pubitemid 43980602)
7. Roy A, Roberts I, Norton A, et al: Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: A multi-step model of myeloid leukaemogenesis. Br J Haematol 147:3-12, 2009
8. Taub JW, Huang X, Matherly LH, et al: Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94:1393-1400, 1999 (Pubitemid 29380420)
9. Ge Y, Stout ML, Tatman DA, et al: GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 97:226-231, 2005 (Pubitemid 40277373)
10. Lange BJ, Kobrinsky N, Barnard DR, et al: Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 91:608-615, 1998 (Pubitemid 28053385)